OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

CurrentBlue KCPolicy POL-PP-273

Diagnostic Testing of Common Sexually Transmitted Infections

Customize your policy alerts

Sign up for Blue KC Policy POL-PP-273 alerts

Get alerted when Policy POL-PP-273 changes without checking for updates manually.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Defines reimbursement and coverage criteria for diagnostic laboratory testing for common STIs (C. trachomatis, N. gonorrhoeae, T. pallidum, T. vaginalis and selected others) for Blue KC lines of business and provider types.

Policy Summary

PayerBlue KC

PolicyDiagnostic Testing of Common Sexually Transmitted Infections

Policy CodePolicy POL-PP-273

Change TypeNo material clinical or coverage changes

Effective DateOct 1, 2025

Last ReviewOct 1, 2026

Next Review DateOct 1, 2026

Key ActionConfirm syphilis antibody positives with both treponemal and nontreponemal tests per standard or reverse algorithm.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

4Primary pathogens

MultipleLOBs impacted

~40+Recognized codes

IncludedMycoplasma genitalium

ReferencedResistance assays

Coverage Criteria for STI Diagnostic Testing

Syphilis antibody testing - covered indications

Covered when any of the following are met

Syphilis antibody testing indications: For any asymptomatic person in a high-risk category: once-a-year assessment using either a standard or reverse algorithm that includes initial and confirmatory testing (treponemal and nontreponemal tests, e.g., treponemal Ig and nontreponemal Ig).

See Notes 1 & 2 for definitions of high-risk.

Symptomatic individuals: Diagnosis of any person presenting with signs and/or symptoms of syphilis infection.

See Note 3 for signs/symptoms.

Increased-frequency screening for MSM/HIV+ men: Once every three months for HIV-positive men or men who have sex with men (MSM).

Policy Summary

PayerBlue KC

PolicyDiagnostic Testing of Common Sexually Transmitted Infections

Policy CodePolicy POL-PP-273

Change TypeNo material clinical or coverage changes

Effective DateOct 1, 2025

Last ReviewOct 1, 2026

Next Review DateOct 1, 2026

Key ActionConfirm syphilis antibody positives with both treponemal and nontreponemal tests per standard or reverse algorithm.

SourceLink

On This Page

Pre-transplant assessment: Treponemal and nontreponemal testing (once prior to transplant) as part of pre-transplant assessment in both donors and recipients of allogeneic hematopoietic stem cell transplantation (allo-HCT).

Test of cure: When a nontreponemal test is used as a test of cure (TOC) for a previously positive syphilis infection.

Asymptomatic, non-high-risk exceptions: For asymptomatic individuals NOT in a high-risk category, antibody screening may be reimbursed only as part of newborn screening, follow-up in a victim of sexual assault, or annually for sexually active individuals under age 18.

Syphilis molecular testing - not covered

Not covered

Syphilis PCR/NAAT: Polymerase chain reaction (PCR) testing and nucleic acid amplification testing (NAAT) for syphilis may not be reimbursed.

Chlamydia NAAT - covered indications

Covered when any of the following are met

Chlamydia NAAT indications: Once-a-year assessment for any asymptomatic person in a high-risk category. Diagnosis of any person presenting with signs or symptoms of chlamydial infection. Diagnosis of suspected lymphogranuloma venereum (LGV). At least three months after initial chlamydial diagnosis when used as a test of cure (TOC).

For asymptomatic individuals not in a high-risk category, screening reimbursable only for newborn screening, sexual assault follow-up, or sexually active individuals <18 years annually.

Chlamydia serology - not covered

Not covered

Chlamydia serology: Serology testing for Chlamydia trachomatis or lymphogranuloma venereum (LGV) may not be reimbursed.

Gonorrhea NAAT and culture

Covered when any of the following are met

Gonorrhea NAAT indications: Once-a-year assessment for any asymptomatic person in a high-risk category. Diagnosis of any person presenting with signs or symptoms of gonorrheal infection. Use as a test of cure (TOC) following treatment. For individuals not responding to initial treatment, culture for Neisseria gonorrhoeae to determine antimicrobial susceptibility may be reimbursed.

For asymptomatic non-high-risk individuals, NAAT screening reimbursable only for newborn screening, sexual assault follow-up, or sexually active individuals <18 years annually.

Trichomonas testing

Covered when any of the following are met

Trichomonas NAAT indications: Symptomatic individuals. Follow-up testing a minimum of three months after initial trichomoniasis diagnosis. Annual screening for symptomatic individuals in high-risk groups. Annual screening for asymptomatic individuals with HIV. As part of follow-up in a victim of sexual assault.

Rapid enzyme immunoassay identification for Trichomonas may not be reimbursed.

Mycoplasma genitalium testing

Covered when condition met

M. genitalium NAAT indications: Qualitative NAAT testing for Mycoplasma genitalium may be reimbursed for symptomatic individuals. Screening asymptomatic individuals for M. genitalium using NAAT may not be reimbursed.

See Note 9 for signs and symptoms that support testing (eg, dysuria, urethral pruritus, purulent or mucopurulent discharge in men; vaginal discharge, itching, dysuria, pelvic discomfort in women).

HSV testing

Covered when condition met

HSV NAAT and serology: Qualitative NAAT for HSV-1 or HSV-2 may be covered for individuals with active genital ulcers or mucocutaneous lesions. Type-specific serologic testing for HSV-2 (glycoprotein G2) may be reimbursed for recurrent/atypical genital symptoms with negative PCR/culture, for clinical diagnosis when PCR/culture are negative or absent, or when an individual's partner has genital herpes. Immunoassay testing for HSV-1 or non-type-specific herpes serology for asymptomatic screening may not be reimbursed.

HPV testing - coverage stance

Covered when specific indications met

HPV testing indications: NAAT testing for high-risk HPV may be reimbursed in the diagnosis and/or assessment of cancer or cancer therapy (for example, p16 immunohistochemistry or HR-HPV testing).

HPV testing is not reimbursed as part of general STI screening panels for asymptomatic individuals, for anogenital wart diagnosis, or for low-risk HPV types.

PrEP-related STI screening

Covered when following schedule applied

PrEP initiation/monitoring testing: Prior to starting PrEP: hepatitis B screening panel (HBsAg, anti-HBs, anti-HBc) may be reimbursed. For PrEP monitoring: qualitative NAAT screening for gonorrhea and chlamydia once every 3 months for MSM and individuals with child-bearing potential, once every 6 months for sexually active individuals; blood testing for syphilis once every 3 months for MSM and once every 6 months for sexually active individuals.

Multitarget PCR panels

Covered when condition met

Multitarget PCR (limited targets): When an individual meets covered conditions for testing (eg, symptomatic or meeting screening criteria), multitarget PCR panels limited to Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis, and Mycoplasma genitalium may be reimbursed.

Recognized diagnostic tests - covered diagnostic tests and proprietary assays listed

Covered diagnostic tests and proprietary assays listed

Listed tests: Recognized CPT/HCPCS and proprietary test codes are enumerated for STI diagnostics, including NAATs for CT, NG, TV, MG and molecular resistance tests (eg, 0402U, 0455U multiplex assays; 0483U gyrA S91F ciprofloxacin resistance for N. gonorrhoeae; 0484U 23S rRNA macrolide resistance for M. genitalium). Coverage applies to these listed codes when clinical indications in the policy are met.

Check payer-specific prior authorization or benefit coverage rules for proprietary assay codes.

The policy states that direct probe detection and/or quantitative NAAT for several organisms may not be reimbursed due to insufficient evidence. Specifically, direct probe detection and/or quantitative NAAT for Chlamydia trachomatis, Neisseria gonorrhoeae, Herpes simplex virus‑1, Herpes simplex virus‑2, Human papillomavirus, and Treponema pallidum are listed as not meeting coverage criteria. This limitation applies even where NAAT methods are discussed elsewhere for specific clinical indications; providers should confirm that the requested NAAT method and code align with the policy’s recognized covered NAAT indications and codes before submitting claims.

Within the cited material there are no additional explicit exclusions beyond those enumerated in the policy text. Providers should rely on the listed non‑coverage items (e.g., specific direct probe/quantitative NAAT exclusions) and the coverage criteria for individual tests; operational exceptions or payer‑specific rules should be checked with the benefit administrator.

The policy specifies that immunoassay testing for HSV-1 and non‑type‑specific herpes serology is generally not reimbursed, and that type‑specific HSV-2 serology (gG2) may be reimbursed only for defined clinical situations (recurrent/atypical symptoms with negative PCR/culture, clinical diagnosis when PCR/culture are negative or absent, or when a partner has genital herpes). For HPV, NAAT testing for high‑risk types is reimbursable when used in the diagnosis or assessment of cancer or cancer therapy (for example, p16 immunohistochemistry or HR‑HPV testing), but HPV testing is not reimbursed as part of general STI screening panels for asymptomatic individuals or for low‑risk/type testing or anogenital wart diagnosis.

The reviewed chunks do not list any additional conditions explicitly labeled as not medically necessary beyond the immunoassay and panel exclusions described elsewhere. Where 'not reimbursed' or 'does not meet coverage criteria' is used in the policy, treat those as the operational non‑coverage positions; if clarification is needed for a specific clinical scenario, contact the payer or review benefit plan language.

Coding and Frequency Guidance

Enumerated laboratory CPT codesCPT

86704	Hepatitis B core antibody (HBcAb); total
86706	Hepatitis B surface antibody (HBsAb)
86780	Antibody; Treponema pallidum
87081	Culture, presumptive, pathogenic organisms, screening only
87110	Culture, Chlamydia, any source
87181	Susceptibility studies, antimicrobial agent; agar dilution method, per agent
87340	Infectious agent antigen detection by immunoassay technique; hepatitis B surface antigen (HBsAg)
87490	Infectious agent detection by nucleic acid; Chlamydia trachomatis, direct probe technique
87491	Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe technique
87492	Infectious agent detection by nucleic acid; Chlamydia trachomatis, quantification

1–10 of 14

1/2

Recognized CPT/HCPCS/proprietary test codesmixed

86704	Hepatitis B core antibody (HBcAb); total
86706	Hepatitis B surface antibody (HBsAb)
86780	Antibody; Treponema pallidum
87081	Culture, presumptive, pathogenic organisms, screening only
87110	Culture, Chlamydia, any source
87181	Susceptibility studies, antimicrobial agent; agar dilution method, per agent
87340	Infectious agent antigen detection by immunoassay; hepatitis B surface antigen (HBsAg)
87490	Infectious agent detection by nucleic acid; Chlamydia trachomatis, direct probe
87491	Chlamydia trachomatis, amplified probe technique
87492	Chlamydia trachomatis, quantification

1–10 of 40

1/4

Screening frequency examples

Syphilis screening frequencyOnce yearly for any asymptomatic person in a high‑risk category; once every 3 months for HIV‑positive men or men who have sex with men (MSM).

Syphilis testing when symptomaticAt presentation for any person with signs or symptoms of syphilis (diagnostic testing).

Syphilis pre‑transplantTreponemal and nontreponemal testing once prior to allogeneic HCT for donors and recipients as part of pre‑transplant assessment.

Syphilis test of cure (TOC)Nontreponemal testing may be used as a test of cure following treatment.

Resistance mutation

N. gonorrhoeae resistance markergyrA S91F point mutation associated with ciprofloxacin (fluoroquinolone) resistance in Neisseria gonorrhoeae.

M. genitalium resistance marker23S rRNA point mutation associated with macrolide resistance in Mycoplasma genitalium.

Assay reportingProprietary assays report probability/algorithmic interpretation of resistance for specified specimen types (oral, rectal, vaginal swabs).

Provider Actions, Documentation, and Authorization

Prior Authorization

Prior Authorization May Apply for Proprietary/Multiplex STI Assays

Prior authorization may be required for certain proprietary or multiplex STI assay codes. Coverage is determined by the member's benefit at the time of request; confirm prior authorization requirements with the payer before ordering proprietary multiplex panels (examples include Abbott Alinity m STI Assay and other listed proprietary tests).

Examples of proprietary/multiplex assays that may require prior authorization: 0402U (Bio-Rad multiplex: C. trachomatis, N. gonorrhoeae, T. vaginalis, M. genitalium), 0455U and Abbott Alinity m STI Assay, other proprietary codes listed (e.g., 0463U, 0483U, 0484U).
Verify member benefit and obtain prior authorization when required before sending proprietary/multiplex STI panels.

Billing Rule

Nonreimbursable Molecular Tests

Certain molecular tests are not reimbursable. PCR and NAAT for syphilis, and serology for chlamydia or LGV, are specifically noted as may not be reimbursed. Document medical necessity and consider alternative covered methods when appropriate.

PCR testing and NAAT for syphilis may not be reimbursed.
Serology testing for Chlamydia or LGV may not be reimbursed.
When molecular testing is clinically indicated but not covered, document rationale and consider culture-based or other covered diagnostic options (e.g., culture for N. gonorrhoeae when antimicrobial susceptibility testing is needed).

Denial Risk

Denial Risk — Documentation and Benefit Verification

No explicit denial triggers are listed in these provider-action notes; however, coverage decisions depend on benefit validation and clinical documentation. Absence of required documentation or use of non-covered tests may result in denial.

Coverage is subject to the individual's benefits at time of request — verify eligibility and covered services prior to testing.
Lack of clinical indication, missing documentation of signs/symptoms, or ordering nonreimbursable tests may lead to claim denial.

Documentation Required

Syphilis Antibody Testing — Confirmation and Reimbursable Scenarios

Syphilis antibody testing requires initial and confirmatory testing for any positive result following standard or reverse algorithms. Reimbursement is supported for screening and diagnostic scenarios as specified (including high-risk asymptomatic persons, symptomatic persons, certain follow-up and transplant situations, and newborn/assault/young sexually active exceptions).

Confirm any initial positive syphilis antibody test with both treponemal and nontreponemal testing as appropriate (e.g., treponemal Ig and nontreponemal test).
Reimbursable scenarios include: annual screening for asymptomatic high-risk persons; diagnosis for symptomatic persons; once every three months for HIV-positive men/MSM; pre-transplant donor/recipient testing; test-of-cure using nontreponemal test; newborn screening; sexual assault follow-up; annually for sexually active individuals <18 years.

Documentation Required

Documented Signs and Symptoms Required for M. genitalium Testing

Document signs and symptoms consistent with Mycoplasma genitalium infection when ordering M. genitalium testing. Clinical documentation should match the recognized presentations for the site of infection.

Men: dysuria, urethral pruritus, purulent or mucopurulent urethral discharge.
Women (cervicitis): vaginal discharge, vaginal itching, dysuria, pelvic discomfort.
PID due to M. genitalium: mild to severe pelvic or abdominal pain, abnormal vaginal discharge, and/or bleeding.

Documentation Required

Provider Actions — Coding, Documentation, and Authorization

Provider action: Use listed CPT and proprietary codes appropriately and ensure documentation supports coverage. Verify if specific proprietary resistance and multiplex assays (e.g., macrolide resistance testing, ciprofloxacin resistance testing) require prior authorization or have special billing considerations.

Relevant CPT examples: 87563 (M. genitalium NAAT), 86780 (Treponema pallidum antibody), culture and susceptibility codes (87081, 87110, 87181).
Proprietary/resistance tests noted: 0483U (ciprofloxacin resistance for N. gonorrhoeae), 0484U (macrolide resistance for M. genitalium), and other proprietary assay codes listed in the policy — confirm coverage and authorization requirements before ordering.

Background

Sexually transmitted infections (STIs) are caused by bacteria, viruses, and other organisms transmitted through sexual contact and can lead to significant sequelae. Examples and potential complications highlighted in the policy include pelvic inflammatory disease and infertility (commonly associated with chlamydia and gonorrhea), neurologic and cardiac disease related to syphilis, and oncogenic risk from certain high‑risk human papillomavirus (HPV) types. Risk factors referenced include multiple sexual partners, men who have sex with men (MSM), prior STI history, incarceration, and socioeconomic factors; these risk designations are used in the policy to define screening frequency and covered testing indications.

Definitions

STI — definition and examples

DefinitionSexually transmitted infections (STIs) are infections caused by bacteria, viruses, or other microorganisms transmitted through sexual contact. Examples include Chlamydia trachomatis, Neisseria gonorrhoeae, Treponema pallidum (syphilis), Trichomonas vaginalis, Mycoplasma genitalium, HPV, and HSV.

Clinical impactUntreated STIs can cause pelvic inflammatory disease, infertility, pregnancy complications, neurologic and cardiac disease (syphilis), and cancers (HPV).

Risk factorsMultiple sex partners, MSM, prior STI, correctional facility admission, and lower socioeconomic status increase risk.

NAAT — nucleic acid amplification test

NAAT definitionNucleic acid amplification test (NAAT): a molecular test detecting DNA or RNA of infectious agents (eg, amplified probe techniques for C. trachomatis, N. gonorrhoeae, T. vaginalis, M. genitalium).

Typical usesUsed for diagnosis of symptomatic individuals and routine screening in high‑risk asymptomatic persons per policy indications.

LimitationsDirect probe detection and some quantitative NAATs may not meet coverage for certain organisms per policy; check specific indications.

Resistance assay — definition and examples

Resistance assay definitionMolecular resistance assay: a test that detects point mutations associated with antibiotic resistance (eg, gyrA S91F for N. gonorrhoeae; 23S rRNA point mutation for M. genitalium).

ExamplesProprietary CPT‑listed assays include ciprofloxacin susceptibility (gyrA S91F) for N. gonorrhoeae (0483U) and macrolide resistance (23S rRNA) for M. genitalium (0484U).

Specimens and reportingPerformed on oral, rectal, or vaginal swabs; results often reported as an algorithmic probability of resistance.